Research papers

Search for

Medication research papers

Large differences in levodopa dose requirement in Parkinson's disease: men use higher doses than womenStudy concludes that the levodopa requirement in Parkinson's ranges considerably, and that men use higher levodopa dose than women. 04 January 2010
Long-term antidyskinetic efficacy of amantadine in Parkinson's diseaseThis study was performed to assess the long-term antidyskinetic effect of amantadine in PD patients. The findings argue for long-term antidyskinetic efficacy of amantadine in PD patients with LID's. 02 March 2010
Genitourinary dysfunction in Parkinson's diseaseBladder dysfunction (urinary urgency/frequency) and sexual dysfunction (erectile dysfunction) are common nonmotor disorders in Parkinson's disease (PD). In contrast to motor disorders, genitourinary autonomic dysfunctions are often nonresponsive to levodopa treatment. 13 January 2010
Dopamine agonist withdrawal syndrome in Parkinson diseaseDopamine agonists have a stereotyped withdrawal syndrome that can lead to profound disability in a subset of patients. 13 January 2010
Orodispersible sublingual piribedil to abort OFF episodesA single dose placebo-controlled, randomized, double-blind, cross-over study. S90049, a novel sublingual formulation of the non-ergoline D(2)-D(3) agonist piribedil, has a pharmacokinetic profile promising to provide rapid relief on motor signs in Parkinson's disease (PD). 12 January 2010
Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trialSialorrhea affects approximately 75% of patients with Parkinson disease (PD). Sialorrhea is often treated with anticholinergics, but central side effects limit their usefulness. 16 April 2010
Serotonin 2A receptors and visual hallucinations in Parkinson diseaseComplex visual hallucinations (VHs) occur in several pathologic conditions; however, the neural mechanisms underlying these symptoms remain unclear. Although dopamine may have a role, indirect evidence indicates that serotonin may also contribute to the pathogenesis of complex VHs, probably via involvement of the serotonin 2 receptor. 14 April 2010
Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervationApathy has been reported to occur after subthalamic nucleus stimulation, a treatment of motor complications in advanced Parkinson's disease. We carried out a prospective study of the occurrence of apathy and associated symptoms, predictors and mechanisms in the year following subthalamic stimulation. 22 March 2010
Dopaminergic modulation of striato-frontal connectivity during motor timing in Parkinson's diseasePatients with Parkinson's disease experience motor and perceptual timing difficulties, which are ameliorated by dopaminergic medication. We investigated the neural correlates of motor timing in Parkinson's disease, including the effects of dopaminergic medication on patterns of brain activation. 16 March 2010
Effect of histamine H(2) receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's diseaseThe use of nondopaminergic agents as adjuncts to levodopa are potential options for managing these problems. Here, we asses the ability of the clinically available, selective histamine H(2) antagonist, famotidine (1, 3, and 30 mg/kg) to treat levodopa-induced dyskinesia and wearing off in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-macaque model of PD. 29 March 2010

Page: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [+11]

[ Next » ]